Literature DB >> 32550157

Whole body vibration showed beneficial effect on pain, balance measures and quality of life in painful diabetic peripheral neuropathy: a randomized controlled trial.

Albina Jamal1, Irshad Ahmad1, Nisar Ahamed1, Muhammad Azharuddin1, Farhan Alam1, M Ejaz Hussain1.   

Abstract

PURPOSE: The aim of the study was to determine the efficacy of whole body vibration (WBV) therapy on pain, neuropathy disability score, balance, proprioception and quality of life (QOL) in patients with painful diabetic peripheral neuropathy (PDPN).
METHODS: Twenty-six (16 males and 10 females) patients with PDPN were selected on the basis of inclusion and exclusion criteria. Subjects were randomly allocated to an experimental group (n = 13, age = 60.69 ± 5.08) and a control group (n = 13, age = 59.54 ± 4.25). The experimental group was given WBV therapy for six weeks (3 days/week) in addition to standard medical care, dietary advice and lifestyle modifications. Control group was provided only standard medical care, dietary advice and lifestyle modifications. Outcome measures included numeric pain rating scale (NPRS), Leeds assessment of neuropathic symptoms and signs (LANSS), vibration perception threshold (VPT), neuropathy disability score (NDS), proprioception, single-leg stance test (SLST), timed up and go test (TUGT) and short form 36 questionnaire (SF-36).
RESULTS: NPRS, LANSS, NDS, SLST and TUGT showed significant time effect (p ≤ 0.022) and time×group interaction (p ≤ 0.007), whereas group effect was found to be significant only in LANSS (p = 0.001). VPT showed significant group effect (p ≤ 0.045) and time×group interaction (p ≤ 0.007) at great toe, metatarsal head and total average score. SF-36 was found to be significant time effect (p ≤ 0.024) in all domains except limitations due to physical health (p = 0.461). SF-36 average score was found be significant for group effect (p = 0.002) and time×group interaction (p < 0.001).
CONCLUSION: WBV improves sensory sensations like pain and vibration perception, neuropathy disability score, balance measures and health-related QOL in PDPN. © Springer Nature Switzerland AG 2019.

Entities:  

Keywords:  Diabetic neuropathy; Neuropathy disability score; SF-36; Single leg stance; Timed up and go

Year:  2019        PMID: 32550157      PMCID: PMC7270395          DOI: 10.1007/s40200-019-00476-1

Source DB:  PubMed          Journal:  J Diabetes Metab Disord        ISSN: 2251-6581


  55 in total

1.  Evaluation of three screening tests and a risk assessment model for diagnosing peripheral neuropathy in the diabetes clinic.

Authors:  D Olaleye; B A Perkins; V Bril
Journal:  Diabetes Res Clin Pract       Date:  2001-11       Impact factor: 5.602

2.  Effects of Whole Body Vibration on Glycemic Indices and Peripheral Blood Flow in Type II Diabetic Patients.

Authors:  Nuttaset Manimmanakorn; Apiwan Manimmanakorn; Warinthorn Phuttharak; Michael J Hamlin
Journal:  Malays J Med Sci       Date:  2017-08-18

3.  Effects of supervised whole body vibration exercise on fall risk factors, functional dependence and health-related quality of life in nursing home residents aged 80+.

Authors:  Francisco Álvarez-Barbosa; Jesús del Pozo-Cruz; Borja del Pozo-Cruz; Rosa M Alfonso-Rosa; Michael E Rogers; Yanxin Zhang
Journal:  Maturitas       Date:  2014-09-30       Impact factor: 4.342

4.  Spinal reflex excitability and homosynaptic depression after a bout of whole-body vibration.

Authors:  Kristof Kipp; Samuel T Johnson; Jeffrey R Doeringer; Mark A Hoffman
Journal:  Muscle Nerve       Date:  2011-02       Impact factor: 3.217

5.  Vibration perception threshold testing in patients with diabetic neuropathy: ceiling effects and reliability.

Authors:  R W van Deursen; M M Sanchez; J A Derr; M B Becker; J S Ulbrecht; P R Cavanagh
Journal:  Diabet Med       Date:  2001-06       Impact factor: 4.359

6.  Correlation between nerve conduction studies and clinical scores in diabetic neuropathy.

Authors:  I Feki; J P Lefaucheur
Journal:  Muscle Nerve       Date:  2001-04       Impact factor: 3.217

7.  Effects of a 12-wk whole-body vibration based intervention to improve type 2 diabetes.

Authors:  Borja del Pozo-Cruz; Rosa M Alfonso-Rosa; Jesus del Pozo-Cruz; Borja Sañudo; Michael E Rogers
Journal:  Maturitas       Date:  2013-09-18       Impact factor: 4.342

Review 8.  Understanding the impact of painful diabetic neuropathy.

Authors:  Cristian Quattrini; Solomon Tesfaye
Journal:  Diabetes Metab Res Rev       Date:  2003 Jan-Feb       Impact factor: 4.876

9.  Validation of the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) questionnaire and its correlation with visual analog pain scales in Greek population.

Authors:  Konstantinos Spanos; Vasileios A Lachanas; Philip Chan; Alexandra Bargiota; Athanasios D Giannoukas
Journal:  J Diabetes Complications       Date:  2015-08-13       Impact factor: 2.852

10.  An overview of randomization techniques: An unbiased assessment of outcome in clinical research.

Authors:  Kp Suresh
Journal:  J Hum Reprod Sci       Date:  2011-01
View more
  3 in total

1.  Low Vibrational Training as an Additional Intervention for Postural Balance, Balance Confidence and Functional Mobility in Type 2 Diabetic Patients with Lower Limb Burn Injury: A Randomized Clinical Trial.

Authors:  Zizi M Ibrahim; Olfat Ibrahim Ali; Samah A Moawd; Marwa M Eid; Mona Mohamed Taha
Journal:  Diabetes Metab Syndr Obes       Date:  2021-08-11       Impact factor: 3.168

Review 2.  Effects of vibration training on quality of life in older adults: a preliminary systematic review and meta-analysis.

Authors:  Rebekah Buehler; Caroline Simpkins; Feng Yang
Journal:  Qual Life Res       Date:  2022-04-09       Impact factor: 3.440

3.  Physical Exercise with or without Whole-Body Vibration in Breast Cancer Patients Suffering from Aromatase Inhibitor-Induced Musculoskeletal Symptoms: A Pilot Randomized Clinical Study.

Authors:  Alessandro de Sire; Lorenzo Lippi; Antonio Ammendolia; Carlo Cisari; Konstantinos Venetis; Elham Sajjadi; Nicola Fusco; Marco Invernizzi
Journal:  J Pers Med       Date:  2021-12-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.